Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
What can we learn from brain autopsies in COVID-19?

Shibani S. Mukerji a, b, *, Isaac H. Solomon b

a Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
b Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States

ARTICLE INFO

Keywords:
COVID-19
SARS-CoV-2
Brain autopsies
Neuropathology
Neuropathogenesis
Immunohistochemistry
Reverse transcriptase polymerase chain reaction

ABSTRACT

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19) for which there have been over 50 million confirmed cases and 1.2 million deaths globally. While many SARS-CoV-2 infected individuals are asymptomatic or experience respiratory symptoms, extrapulmonary manifestations, including neurological symptoms and conditions, are increasingly recognized. There remains no clear understanding of the mechanisms that underlie neurological symptoms in COVID-19 and whether SARS-CoV-2 has the potential for neuroinvasion in humans. In this minireview, we discuss what is known from human autopsies in fatal COVID-19, including highlighting studies that investigate for the presence of SARS-CoV-2 in brain and olfactory tissue, and summarize the neuropathological consequences of infection. Incorporating microscopic and molecular findings from brain tissue into what we know about clinical disease will inform best practice management guidance and direct research priorities as it relates to neurological morbidity from COVID-19.

1. Manuscript

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an enveloped, single-stranded positive-sense RNA betacoronavirus, is the causative agent of coronavirus disease 2019 (COVID-19), for which there have been over 50 million confirmed cases and 1.2 millions deaths worldwide as of November 8, 2020 [1, 2]. Morbidity and mortality are more common in older individuals and those with comorbidities, including cardiovascular disease, hypertension, obesity, and diabetes, although young people with no comorbidities are also at risk for critical illness [3–5]. While many SARS-CoV-2 infected individuals are asymptomatic or experience predominantly respiratory symptoms, extrapulmonary manifestations, including neurological symptoms and conditions, are increasingly recognized [6–8]. The majority of current studies on neurological manifestations are case reports or retrospective series focused on hospitalized patients through the extraction of medical record data, which have described disorders of consciousness, delirium, and neuromuscular and cerebrovascular complications [7–10]. Smell and taste disturbances in the absence of nasal obstruction are particularly characteristic of COVID-19, leading to speculation regarding the olfactory nerve as a possible route of central nervous system entry [11, 12]. Other neurological findings include headache, myalgia, rhodomyelitis, Guillain-Barre syndrome, encephalopathy, and myelopathy with rare cases of encephalitis based on imaging or cerebrospinal fluid [8, 13–18]. SARS-CoV-2 has not been detected in cerebrospinal fluid in the majority of patients tested [8, 19], highlighting the need for studies of autopsy brain tissue to understand COVID-19 neuropathogenesis and develop neurocognitive preserving treatment strategies.

Autopsies provide a wealth of information about the decedents, regardless of whether a likely cause of death was identified pre-mortem [20, 21]. Due to initial uncertainties regarding the infectious properties of SARS-CoV-2 and limitations in personnel and personal protective equipment availability, autopsies for COVID-19 patients have been limited, although an increasing number of studies are now being published (reviewed in [22–24]). Reports of detailed neuropathological examinations have lagged behind general autopsy series, in part due to the initial focus on lung pathology combined with the longer (2–3 weeks) formalin fixation time preferred by most neuropathologists before cutting brains. Additional factors include the reluctance of some institutions to perform brain removal in COVID-19 cases due to concerns over electric bone saw generated aerosols, which can be effectively contained through the use of vacuum filters or hand saws [25, 26]. Included in this review are peer-reviewed studies of autopsy findings published in English between January 1, 2020, and November 5, 2020. Two different databases (PubMed, Google Scholar) were searched for key terms, including COVID-19, nCoV-2019, and SARS-CoV-2, crossed

* Corresponding author at: Massachusetts General Hospital, 55 Fruit St Wang 824, Boston, MA, 02114, United States.
E-mail address: smukerji@partners.org (S.S. Mukerji).
| Reference | No. Cases Included; autopsy type | Macroscopic Evaluation | Microscopic Evaluation | SARS-CoV-2 Protein | SARS-CoV-2 RNA |
|-----------|---------------------------------|------------------------|------------------------|---------------------|---------------|
| Puelles et al. 2020 [41] | 43; subset full autopsy with brain findings | Edema (n = 23), fresh territorial infarct (n = 6) | Fresh ischemic infarct (n = 6), astrocytosis, microgliosis, perivascular, parenchymal, and leptomeningeal T cells (n = 43) | Viral spike or nucleocapsid IHC positive in 16/40 cases (rare cells in medulla; 2 cases with vagus or glossopharyngeal nerves) | qRT-PCR positive (13/27; median 4700 viral E gene copies/cell; range <1000 to 162,000) in frontal lobe and/or medulla |
| Wichmann et al. 2020 [49] | 11; full autopsy with brain findings | Recently drained subdural hematoma (n = 1); cerebral hemorrhage (n = 1) | Mild to moderate acute hypoxic injury (n = 3), rare foci of perivascular and leptomeningeal inflammation (n = 3) | Viral nucleocapsid IHC negative in all cases | qRT-PCR positive (n = 5; 5.0–59.4 N1/N2 copies/μL) |
| Matschke et al. 2020 [37] | 10; full autopsy with brain findings | Edema and meningeal congestion (n = 6), paracortical and periarteriolar lymphocytic infiltrates of T cells in white matter, and brain stem (n = 6) | Global hypoxic-ischemic injury (n = 10), perivascular, and/or medulla (n = 10), macro and/or microinfarcts (n = 10); perivascular microhemorrhage (n = 10), microglial activation (n = 5), perivascular/leptomeningeal lymphocytic inflammation (n = 1) | N.A. | qRT-PCR positive in olfactory nerve and brain tissue in (n = 1; RdRp, E, and N genes) |
| Solomon et al. 2020 [17] | 18; brain-only findings | Recently drained subdural hematoma (n = 1); cerebral hemorrhage (n = 1) | Cerebral hemorrhage or hemorrhagic suffusion (n = 8); focal ischemic necrosis (n = 3), edema and/or vascular congestions (n = 5), diffuse or focal spongiosis (n = 10) | Viral nucleocapsid IHC negative in all cases | qRT-PCR positive (n = 9; viral E gene; Ct: 28.67–35.11) |
| Remmelink et al. 2020 [38] | 11; full autopsy with brain findings | Recently drained subdural hematoma (n = 1); cerebral hemorrhage (n = 1) | Visceral ischemia (n = 3), focal hypoxic injury and brain herniation (n = 1), microthrombi in brain vessels (n = 10), axonal degeneration (n = 3) | Viral nucleocapsid IHC negative in 11 cases | N.A. |
| Schurink et al. 2020 [36] | 10; full autopsy with brain findings | Edema and meningeal congestion (n = 10), focal hypoxic injury, and/or medulla (n = 10) | Viral nucleocapsid IHC negative in all cases | N.A. | N.A. |
| Fabbri et al. 2020 [50] | 10; full autopsy with brain findings | Edema and meningeal congestion (n = 10), paracortical and periarteriolar lymphocytic infiltrates of T cells in white matter, and brain stem (n = 10) | Viral nucleocapsid IHC negative in all cases | N.A. | N.A. |
| Schaller et al. 2020 [51] | 10; full autopsy with brain findings | Edema and meningeal congestion (n = 10), paracortical and periarteriolar lymphocytic infiltrates of T cells in white matter, and brain stem (n = 10) | Viral nucleocapsid IHC negative in all cases | N.A. | N.A. |
| Hanley et al. 2020 [34] | 9; full autopsy with brain findings | Hemorrhagic conversion of middle cerebral artery stroke (n = 1) | Moderate to intense microglial activation; mild T-cell infiltrate around blood vessels and capillaries, and ischemic changes of variable extent in the neurons of the cortex and the white matter (n = 5) | No specific findings | qRT-PCR positive (n = 4; 10^3 to 10^4 viral E gene copies per μg total RNA); Subgenomic viral RNA positive (n = 1; Ct: −32) |
| Deigendesch et al. 2020 [33] | 7; full autopsy with brain findings | Moderate global brain edema without cerebral mass displacement (n = 1) | Microglial activation in pons, medulla, and olfactory bulb; sparse perivascular and leptomeningeal infiltrates of lymphocytes; mild acute hypoxic-ischemic encephalopathy (n = 3) | N.A. | qRT-PCR positive in olfactory bulb (n = 4), optic nerve (n = 2); not detected in brainstem or cerebellum (ORFab1, S, and N genes) |
| Menter et al. 2020 [26] | 6; full autopsy with brain findings | Massive hemorrhage and herniation (n = 2); petechial bleedings (n = 4) | Hypoxic alterations (n = 6); lymphocytic meningitis and encephalitis (n = 6); brainstem neuronal cell loss in (n = 4), axon degeneration (n = 3) | N.A. | N.A. |
| von Weyharn et al. 2020 [27] | 5; full autopsy with brain findings | Scattered punctate subarachnoid hemorrhages (n = 1) | Rare microhemorrhages in the brainstem (n = 1) | N.A. | N.A. |
| Bradley et al. 2020 [28] | 4; full autopsy with brain findings | Mild brain swelling, discoloration of watershed areas, lacunar infarcts, and microinfarctions in cerebral and cerebellar white matter, deep gray matter, and brain stem (n = 1) | High density acute microhemorrhages, severe hypoxic-ischemic injury, scattered T lymphocytes, and axonal spheroids (n = 1); mild to moderate hypoxic-ischemic injury (n = 3) | Viral spike IHC negative in brain, olfactory mucosa, and carotid body | qRT-PCR negative in brain and olfactory mucosa (RdRp, N, and E genes) |
| Kirschenbaum et al. 2020 [39] | 3; full autopsy with brain findings | N.A. | Glialosis, neuronal loss, vascular rarefaction | N.A. | N.A. |
| Barton et al. 2020 [52] | 2; full autopsy with brain findings | No gross abnormalities | N.A. | N.A. | N.A. |
| Jaumuktane et al. 2020 [29] | 2; brain-only findings | Large acute and subacute infarcts (n = 1); white matter microhemorrhages and microinfarcts (n = 1) | Hemorrhages and infarcts (n = 2); mild leptomeningeal inflammation (n = 1) | N.A. | N.A. |
| Fabbri et al. 2020 [31] | 10; full autopsy with brain findings | Edema and meningeal congestion (n = 10), paracortical and periarteriolar lymphocytic infiltrates of T cells in white matter, and brain stem (n = 10) | No specific findings | N.A. | N.A. |

(continued on next page)
Table 1 (continued)

| Reference                        | No. Cases Included; autopsy type | Macroscopic Evaluation                                                                 | Microscopic Evaluation                                                                 | SARS-CoV-2 Protein                       | SARS-CoV-2 RNA                                                                 |
|----------------------------------|---------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------|--------------------------------------------------------------------------------|
| Al-Dalahmah et al. 2020 [33]      | 1; full autopsy with brain findings | Cerebellar hemorrhage, acute infarcts in the dorsal pons and medulla, tonsillar herniation | Perivascular leukocytic infiltrates in basal ganglia and intravascular microthrombi (n = 2); prominent leukocytic infiltrates in olfactory epithelium (n = 2) | Viral nucleocapsid IHC negative         | qRT-PCR positive in nasal epithelium (Mean Ct 31.75, 278 copies/μL RNA), olfactory bulb (Ct 36.70, 11 copies/μL); Cerebellar clot (Ct 33.0, 559 copies/μL), and cerebellum (Ct 37.17, 8 copies/μL); Viral ISH negative N.A. |
| Craver et al. 2020 [53]          | 1; full autopsy with brain findings | No CNS lesions identified                                                                 | No CNS lesions identified                                                                 | N.A.                                   | N.A.                                                                            |
| Dolnikoff et al. 2020 [54]       | 1; full autopsy with brain findings | N.A.                                                                                   | Microglial reactivity                                                                   | N.A.                                   | N.A.                                                                            |
| Lax et al. 2020 [55]             | 1; full autopsy with brain findings | No acute alterations                                                                    | No acute alterations                                                                   | N.A.                                   | N.A.                                                                            |
| Paniz-Mondolfi et al. 2020 [12]  | 1; brain-only findings           | N.A.                                                                                   | N.A.                                                                                   | TEM showed viral like particles in frontal lobe sections | qRT-PCR positive (four different assays targeting ORF1/a and E-gene, N1, N2, N3, N2 and E-gene, and ORF1ab and S genes) N.A. |
| Reichard et al. 2020 [16]        | 1; brain-only findings           | Mild brain swelling and hemorrhagic white matter lesions                                 | Focal hemorrhage, ADEM-like lesions, microinfarcts, damaged axons, hypoxic-ischemic injury | N.A.                                   | N.A.                                                                            |

Abbreviations: ADEM, acute disseminated encephalomyelitis; Ct, cycle threshold; qRT-PCR, quantitative reverse transcriptase polymerase chain reaction; E gene, SARS-CoV-2 envelope gene; ORF1ab, open reading frame 1ab; IHC, immunohistochemistry; ISH, in-situ hybridization; RdRp, RNA-dependent RNA polymerase gene; N.A., not available or evaluated; TEM, transmission electron microscopy.

* Provided data on angiotensin converting enzyme – 2 (ACE2) IHC in brain tissue and olfactory bulb.
with autopsy, histology, histopathology, neuropathology, and post-mortem. This search was complemented with three review articles [22–24], text word searching and examining references in identified articles. A total of 24 studies were identified that included 149 individuals (range 1–43 subjects per series). Reported gross and microscopic findings and results of SARS-CoV-2 targeted studies are summarized in Table 1. Representative gross, microscopic, and ultrastructural findings are illustrated in Fig. 1.

Gross brain autopsy findings were reported individually or in aggregate for 142 subjects. In keeping with the high prevalence of comorbidities in this patient population, evidence of prior brain disease was frequently identified, including neurodegeneration, prior strokes, tumor resection, demyelinating disease, and atherosclerosis. Acute gross abnormalities were much more limited, and a direct causal relationship with SARS-CoV-2 infection was not always straightforward to identify. A total of 92 (65 %) of the gross brain examinations reported either no significant findings or no acute abnormalities. Of the remaining 50 cases, multiple findings were often described in individual brains. Hemorrhage was the most common abnormality reported, ranging from petechial bleedings and punctate subarachnoid hemorrhages (n = 9) [14,27–31], to large cerebral/cerebellar hemorrhages (n = 4) [27,32,33], hemorrhagic conversion of middle cerebral artery stroke (n = 1) [34], and a recently drained subdural hematoma (n = 1) [32]. Large acute and/or subacute infarcts (n = 11) [29,31,33,35] as well as lacunar infarcts/microinfarcts and watershed infarcts (n = 2) [29,30] were identified in several cases. Severe edema resulting in herniation (n = 5) [27,31,33] as well as mild to moderate edema without herniation (n = 34) [14,30,31,35,36] were also present.
Microscopic findings were reported for 146 of the cases in these studies. Similar to the gross examinations, histopathology identified correlates of pre-existing disease, including neurodegeneration, chronic/subacute strokes, hepatic encephalopathy, and arteriolosclerosis. No specific findings were reported for 25 (17 %) of the cases. Mild to moderate acute hypoxic injury was the most common abnormality (n = 58) [14,27,30,31,33,34,36-38], while severe hypoxic-ischemic injury (n = 1) [30] and infarcts/foveal ischemic necrosis (n = 22) [14,29,31,32,35] were identified in several cases. Focal microhemorrhage or hemorrhagic suffusion was also frequently reported (n = 23) [14,28-33], although intravascular microthrombi (n = 12) [31,39] or neutrophilic plugs (n = 3) [38] were less common. Mild focal perivascular, parenchymal, and leptomeningeal T-cell predominant lymphocytic infiltrates were identified in a large number of cases without clear evidence of vasculitis or meningoencephalitis (n = 81) [27,29-31,33-39]. Moderate to intense microglial activation was noted, particularly in the brainstem (n = 73), although similar results were also reported in COVID-19-negative individuals with systemic inflammatory-yeptic clinical courses [31,33-36,38]. Axonal damage was identified in a few cases (n = 5) [14,27,30]. Acute disseminated encephalomyelitis (ADEM)-like lesions were reported in a single case [14]. The olfactory system was examined to varying degrees, identifying prominent acute and chronic inflammation in the olfactory epithelium (n = 14) [33,38,39], microglial activation (n = 18) [36] and red neurons (n = 1) [33] in the olfactory bulb, and only unremarkable age-related corpora amylacea in olfactory tracts.

Researchers across the globe have employed multiple strategies to directly assess for the presence of SARS-CoV-2 in brain tissue, including immunohistochemistry, in situ hybridization (ISH), targeted quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), and transmission electron microscopy. At this time, immunohistochemistry, using antibodies that recognize the viral nucleocapsid (N) or spike (S) proteins, have been negative in most attempted human cases (n = 58) [30,33,35,37,38], with the exception of a recent case series that reported positive staining in vanguard and glossopharyngeal nerves and scattered cells in the medulla in a total of 16 cases [35]; in situ hybridization for viral RNA has been negative (n = 1) [33]. Viral spike protein has been reported to be present in the olfactory epithelium in 5/6 patients; however, brain findings from these cases were not discussed [40]. A number of qRT-PCR assays have been employed targeting the N, S, envelope (E), open reading frame (ORF) 1/a, ORF1ab, or RNA-dependent reverse transcriptase (RdRp) genes, identifying low levels of virus in frozen or formalin-fixed paraffin-embedded brain tissue (34/84; 41 %) [12,30-37,41] and olfactory bulb/tract (n = 9/36; 25 %) [31,33,36,37]. Viral subgenomic RNA, a marker of actively replicating viron, was positive in a single case (n = 1/5; 20 %) [34]. Transmission electron microscopy (TEM) without immunolabeling reported virus-like particles in the frontal lobe (n = 1) [12].

While additional COVID-19 autopsy series continue to be published, the overall picture of acute hypoxic-injury, hemorrhage, and mild to moderate non-specific inflammation is unlikely to change significantly. Evidence of direct viral involvement in the brain or olfactory nerve is limited to the detection of low levels of viral RNA and rare viral antigen in cranial nerves and scattered brainstem cells. Diagnosis of coronavirus particles by electron microscopy is challenging due to similar appearing normal cellular structures, which has created significant controversy in the literature [42,43]. Due to the inherent bias of autopsy studies for severe, fatal diseases, and additional institutional restrictions for which cases include brain evaluation, the frequency and extent of neuropathological findings are likely to be underestimated relative to the average COVID-19 patient. At the time of this review, pediatric autopsies, including individuals with multisystem inflammatory syndrome in children (MIS-C), remain extremely limited. While the number of pediatric COVID-19 cases accounts for <2 % of all cases [44], data obtained from brain tissue in this age-group can help address the unique pathophysiology of SARS-CoV-2 infection, including age-dependent immune-responses, hypercoagulability, and degree of hypoxic-ischemic injury.

Additional remaining areas of interest include characterizing the effects of remdesivir and other potential antiviral therapeutics, immunomodulatory medications including dexamethasone, anti-IL-6 or other monoclonal antibodies, and anticoagulants on brain tissue. Given that the therapeutic response to COVID-19 vastly differs between institutions, it remains a challenge to understand how therapeutic choices during acute hospitalization are responsible for the variability in observed neurological manifestations and neuropathological findings. Also, while not surprisingly this early in the pandemic, long-term neuropathological sequelae in COVID-19 survivors remain unstudied. There is evidence that neurological symptoms, including fatigue and headaches, linger for weeks to months in a subset of affected patients [45,46] and studies determining mechanisms for persistent neurological symptoms are needed.

There have been several efforts for sharing COVID-19 brain tissue, including the International Society of Neuropathology (ISN) Collaborative Efforts [47] and the COVID-19 Virtual Biobank at the University of Nebraska Medical Center [48]. To address many of the remaining unanswered questions regarding the neuropathological effects of COVID-19, large scale integrated studies from multiple institutions with relevant clinical metadata will be crucial. The ongoing collection of neurological tissue will be critical to inform best practice management guidance and to direct research priorities as it relates to neurological morbidity from COVID-19.

Funding sources

S.S.M. was supported by the National Institute of Mental Health at the National Institutes of Health [grant number K23MH115812]. James S. McDonnell Foundation and the Harvard University Eleanor and Miles Shore Fellowship Program. I.H.S. was supported by the National Institute of Neurological Disorders and Stroke at the National Institutes of Health [grant number R21NS19660].

Acknowledgements

We would like to acknowledge all front-line healthcare workers taking care of patients during the COVID-19 pandemic, and patients and their families who contribute research to help understand neurological disease.

References

[1] J.H. University, COVID-19 Map- Johns Hopkins Coronavirus Resource Center, 2020. https://coronavirus.jhu.edu/map.html.
[2] Coronavirus Disease Study Group of the International Committee on Taxonomy of Virus, The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5 (2020) 530-544.
[3] A. Bhimraj, R.L. Morgan, A.H. Shumaker, V. Laveyrenge, L. Baden, V.C.-C. Cheng, K.M. Edwards, R. Gandhi, W.J. Muller, J.C. O’Horo, S. Shoham, M.H. Murad, R. A. Mustafa, S. Sultan, Y. Falck-Ytter, Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19, Clin. Infect. Dis. (2020). https://doi.org/10.1093/cid/ciaa478.
[4] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu, J.A. Xiu, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang, B. Cao, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet 395 (2020) 497-506.
[5] A.B. Docherty, E.M. Harrison, C.A. Green, H.E. Hardwick, R. Pius, L. Norman, K.A. Holden, J.M. Read, F. Dondelinger, G. Carson, L. Merson, J. Lee, D. Plotkin, L. Sigfrid, S. Halpin, C. Jackson, C. Gamble, P.W. Horby, J.S. Nguyen-Van-Tam, A. Ho, C.D. Russell, J. Dunning, P.J. Openshaw, J.K. Baillie, M.G. Semple, ISARIC4C investigators, Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study, BMJ 369 (2020) m1985.
[6] A. Gupta, M.V. Madhavan, K. Sehgal, S. Mahajan, T.S. Sehrawat, B. Bikdeli, N. Abluvalia, J.C. Austello, E.Y. Wan, D.E. Freedberg, A.J. Kirtane, S.A. Parikh, M.S. Maurer, A.S. Nordvig, D. Accili, J.M. Batson, S. Mohan, K.A. Bauer, M.B. Leon, H.M. Krumholz, N. Ureti, M.R. Mehra, M.S.V. Ekind, G.W. Stone,
C.H. von Weyhern, I. Kaufmann, F. Neff, M. Kremer, Early evidence of pronounced S.B. Polak, I.C. Van Gool, D. Cohen, J.H. von der Thüsen, J. van Paassen, S. Abu-Rumeileh, A. Abdelhak, M. Foschi, H. Tumani, M. Otto, Guillain-Barré G.N. McAbee, Y. Brosgol, S. Pavlakis, R. Agha, M. Gaffoor, Encephalitis associated C.M. Romero-Sánchez, I. Díaz-Maroto, Á. Sánchez-Larsen, A. Layos-Joromo, J. García-García, E. González, I. Redondo-Periás, A.B. Perona-Moratalla, J.A. Del Valle-Pérez, J. Gracia-Gil, L. Rojas-Bartolomea, I. Ferre-Vilar, M. Montenegro, M. Falgueras-Palazón, C. Alcázar-Rodríguez, D. Sopenhauer, Garay, Y. Moreno, J. Ahmad, T. Segura, Neurologic manifestations in hospitalized patients with COVID-19: the AL-Hamad, A. Fitzherbert, M. Donde, T. Eadie, L. Gensichen, M. Denzler, C. Hagel, J.P. Sperhake, A.S. Schröder, D. Sereika, M. Shimada, A. first case of meningitis/encephalitis associated with SARS-CoV-2, Lancet Neurol. 140 (2020) 397–400.

G.N. McAbee, Y. Brosgol, S. Pavlakis, R. Agha, M. Gaffoor, Encephalitis associated S.B. Polak, I.C. Van Gool, D. Cohen, J.H. von der Thüsen, J. van Paassen, S. Abu-Rumeileh, A. Abdelhak, M. Foschi, H. Tumani, M. Otto, Guillain-Barré G.N. McAbee, Y. Brosgol, S. Pavlakis, R. Agha, M. Gaffoor, Encephalitis associated S.B. Polak, I.C. Van Gool, D. Cohen, J.H. von der Thüsen, J. van Paassen, S. Abu-Rumeileh, A. Abdelhak, M. Foschi, H. Tumani, M. Otto, Guillain-Barré 6.

G. Deutsch, J.M. Lacy, T. Williams, N. Yarid, D.A. Marshall, Histopathology and neurological associations of COVID-19, Lancet 395 (2020) e109.

R. Campion Jr., I. Diaz, C. Zhang, B.B. Navi, Risk of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) vs patients with influenza, JAMA Neurol. 77 (2020) 311–318.

S. Shimada, A first case of meningitis/encephalitis associated with SARS-COV-2, N. Engl. J. Med. 383 (2020) 559–567.

S. Shimada, A first case of meningitis/encephalitis associated with SARS-COV-2, N. Engl. J. Med. 383 (2020) 559–567.

J. Matschke, M. Lütgehetmann, C. Hagel, J.P. Sperhake, M.N. Wong, A. Layos-Joromo, J. García-García, E. González, I. Redondo-Periás, A.B. Perona-Moratalla, J.A. Del Valle-Pérez, J. Gracia-Gil, L. Rojas-Bartolomea, I. Ferre-Vilar, M. Montenegro, M. Falgueras-Palazón, C. Alcázar-Rodríguez, D. Sopenhauer, Garay, Y. Moreno, J. Ahmad, T. Segura, Neurologic manifestations in hospitalized patients with COVID-19: the AL-Hamad, A. Fitzherbert, M. Donde, T. Eadie, L. Gensichen, M. Denzler, C. Hagel, J.P. Sperhake, A.S. Schröder, D. Sereika, M. Shimada, A. first case of meningitis/encephalitis associated with SARS-CoV-2, Lancet Neurol. 140 (2020) 397–400.

S. Shimada, A first case of meningitis/encephalitis associated with SARS-COV-2, N. Engl. J. Med. 383 (2020) 559–567.
[48] COVID-19 Biorepository, (n.d.). https://covidbank.unmc.edu/ (Accessed September 10, 2020).

[49] D. Wichmann, J.-P. Sperhake, M. Lütgehetmann, S. Steurer, C. Edler, A. Heinemann, F. Heinrich, H. Mushumba, I. Kniep, A.S. Schröder, C. Burdelski, G. de Heer, A. Nierhaus, D. Frings, S. Pfefferle, H. Becker, H. Bredereke-Wiedling, A. de Weerth, H.-R. Paschen, S. Sheikhzadeh-Eggers, A. Stang, S. Schmiedel, C. Bokemeyer, M.M. Addo, M. Aepfelbacher, K. Pürschel, S. Kluge, Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study, Ann. Intern. Med. 173 (2020) 268–277.

[50] T. Schaller, K. Hirschbühl, K. Burkhardt, G. Braun, M. Trepel, B. Märl, R. Claus, Postmortem examination of patients with COVID-19, JAMA (2020), https://doi.org/10.1001/jama.2020.8907.

[51] T. Schaller, K. Hirschbühl, K. Burkhardt, G. Braun, M. Trepel, B. Märl, R. Claus, Postmortem examination of patients with COVID-19, JAMA (2020), https://doi.org/10.1001/jama.2020.8907.

[52] L.M. Barton, E.J. Duval, E. Stroberg, S. Ghosh, S. Mukhopadhyay, COVID-19 Autopsies, Oklahoma, USA, Am. J. Clin. Pathol. 153 (2020) 725–733.

[53] R. Craver, S. Huber, M. Sandomirsky, D. Mechina, J. Schieffelin, L. Finger, Fatal eosinophilic myocarditis in a healthy 17-Year-Old male with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2c), Fetal Pediatr. Pathol. 39 (2020) 263–268.

[54] M. Dolhnikoff, J. Ferreira Ferranti, R.A. de Almeida Monteiro, A.N. Duarte-Neto, M. Soares Gomes-Gouveia, N. Viu Degasparre, A. Figueiredo Delgado, C. Montanari Fiorita, G. Nunes Leal, R.M. Rodrigues, K. Taverna Chaim, J.R. Rebelo Pinho, M. Carneiro-Sampaio, T. Masud, L.F. Ferraz da Silva, W. Brunow de Carvalho, P.H. N. Saldiva, E. Garcia Caldáni, SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem inflammatory syndrome, Lancet Child Adolesc Health. 4 (2020) 790–794.

[55] S.F. Lax, K. Skok, P. Zechner, H.H. Kessler, N. Kaufmann, C. Koeblinger, K. Vander, U. Bargrieder, M. Trauner, Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series, Ann. Intern. Med. 173 (2020) 350–361.